Global Gastric Motility Disorder Drug Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Gastric Motility Disorder Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Gastric Motility Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Gastric Motility Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Gastric Motility Disorder Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Gastric Motility Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Gastric Motility Disorder Drug market include Theravance, Inc., Targacept, Inc., Helsinn Healthcare S.A., Concert Pharmaceuticals, Inc. and ChironWells GmbH, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Gastric Motility Disorder Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Gastric Motility Disorder Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Gastric Motility Disorder Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gastric Motility Disorder Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastric Motility Disorder Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gastric Motility Disorder Drug sales, projected growth trends, production technology, application and end-user industry.
Gastric Motility Disorder Drug Segment by Company
Theravance, Inc.
Targacept, Inc.
Helsinn Healthcare S.A.
Concert Pharmaceuticals, Inc.
ChironWells GmbH
Gastric Motility Disorder Drug Segment by Type
Ipamorelin
Velusetrag
TD-8954
Others
Gastric Motility Disorder Drug Segment by Application
Hospital
Clinic
Home Use
Gastric Motility Disorder Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Gastric Motility Disorder Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Gastric Motility Disorder Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gastric Motility Disorder Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Gastric Motility Disorder Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Motility Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Motility Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Motility Disorder Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gastric Motility Disorder Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastric Motility Disorder Drug industry.
Chapter 3: Detailed analysis of Gastric Motility Disorder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Gastric Motility Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Gastric Motility Disorder Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Gastric Motility Disorder Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Gastric Motility Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Gastric Motility Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Gastric Motility Disorder Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Gastric Motility Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Gastric Motility Disorder Drug market include Theravance, Inc., Targacept, Inc., Helsinn Healthcare S.A., Concert Pharmaceuticals, Inc. and ChironWells GmbH, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Gastric Motility Disorder Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Gastric Motility Disorder Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Gastric Motility Disorder Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gastric Motility Disorder Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastric Motility Disorder Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gastric Motility Disorder Drug sales, projected growth trends, production technology, application and end-user industry.
Gastric Motility Disorder Drug Segment by Company
Theravance, Inc.
Targacept, Inc.
Helsinn Healthcare S.A.
Concert Pharmaceuticals, Inc.
ChironWells GmbH
Gastric Motility Disorder Drug Segment by Type
Ipamorelin
Velusetrag
TD-8954
Others
Gastric Motility Disorder Drug Segment by Application
Hospital
Clinic
Home Use
Gastric Motility Disorder Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Gastric Motility Disorder Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Gastric Motility Disorder Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gastric Motility Disorder Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Gastric Motility Disorder Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Motility Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Motility Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Motility Disorder Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gastric Motility Disorder Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastric Motility Disorder Drug industry.
Chapter 3: Detailed analysis of Gastric Motility Disorder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Gastric Motility Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Gastric Motility Disorder Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
190 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Gastric Motility Disorder Drug Sales Value (2020-2031)
- 1.2.2 Global Gastric Motility Disorder Drug Sales Volume (2020-2031)
- 1.2.3 Global Gastric Motility Disorder Drug Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Gastric Motility Disorder Drug Market Dynamics
- 2.1 Gastric Motility Disorder Drug Industry Trends
- 2.2 Gastric Motility Disorder Drug Industry Drivers
- 2.3 Gastric Motility Disorder Drug Industry Opportunities and Challenges
- 2.4 Gastric Motility Disorder Drug Industry Restraints
- 3 Gastric Motility Disorder Drug Market by Company
- 3.1 Global Gastric Motility Disorder Drug Company Revenue Ranking in 2024
- 3.2 Global Gastric Motility Disorder Drug Revenue by Company (2020-2025)
- 3.3 Global Gastric Motility Disorder Drug Sales Volume by Company (2020-2025)
- 3.4 Global Gastric Motility Disorder Drug Average Price by Company (2020-2025)
- 3.5 Global Gastric Motility Disorder Drug Company Ranking (2023-2025)
- 3.6 Global Gastric Motility Disorder Drug Company Manufacturing Base and Headquarters
- 3.7 Global Gastric Motility Disorder Drug Company Product Type and Application
- 3.8 Global Gastric Motility Disorder Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Gastric Motility Disorder Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Gastric Motility Disorder Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Gastric Motility Disorder Drug Market by Type
- 4.1 Gastric Motility Disorder Drug Type Introduction
- 4.1.1 Ipamorelin
- 4.1.2 Velusetrag
- 4.1.3 TD-8954
- 4.1.4 Others
- 4.2 Global Gastric Motility Disorder Drug Sales Volume by Type
- 4.2.1 Global Gastric Motility Disorder Drug Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Gastric Motility Disorder Drug Sales Volume by Type (2020-2031)
- 4.2.3 Global Gastric Motility Disorder Drug Sales Volume Share by Type (2020-2031)
- 4.3 Global Gastric Motility Disorder Drug Sales Value by Type
- 4.3.1 Global Gastric Motility Disorder Drug Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Gastric Motility Disorder Drug Sales Value by Type (2020-2031)
- 4.3.3 Global Gastric Motility Disorder Drug Sales Value Share by Type (2020-2031)
- 5 Gastric Motility Disorder Drug Market by Application
- 5.1 Gastric Motility Disorder Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Home Use
- 5.2 Global Gastric Motility Disorder Drug Sales Volume by Application
- 5.2.1 Global Gastric Motility Disorder Drug Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Gastric Motility Disorder Drug Sales Volume by Application (2020-2031)
- 5.2.3 Global Gastric Motility Disorder Drug Sales Volume Share by Application (2020-2031)
- 5.3 Global Gastric Motility Disorder Drug Sales Value by Application
- 5.3.1 Global Gastric Motility Disorder Drug Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Gastric Motility Disorder Drug Sales Value by Application (2020-2031)
- 5.3.3 Global Gastric Motility Disorder Drug Sales Value Share by Application (2020-2031)
- 6 Gastric Motility Disorder Drug Regional Sales and Value Analysis
- 6.1 Global Gastric Motility Disorder Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Gastric Motility Disorder Drug Sales by Region (2020-2031)
- 6.2.1 Global Gastric Motility Disorder Drug Sales by Region: 2020-2025
- 6.2.2 Global Gastric Motility Disorder Drug Sales by Region (2026-2031)
- 6.3 Global Gastric Motility Disorder Drug Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Gastric Motility Disorder Drug Sales Value by Region (2020-2031)
- 6.4.1 Global Gastric Motility Disorder Drug Sales Value by Region: 2020-2025
- 6.4.2 Global Gastric Motility Disorder Drug Sales Value by Region (2026-2031)
- 6.5 Global Gastric Motility Disorder Drug Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Gastric Motility Disorder Drug Sales Value (2020-2031)
- 6.6.2 North America Gastric Motility Disorder Drug Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Gastric Motility Disorder Drug Sales Value (2020-2031)
- 6.7.2 Europe Gastric Motility Disorder Drug Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Gastric Motility Disorder Drug Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Gastric Motility Disorder Drug Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Gastric Motility Disorder Drug Sales Value (2020-2031)
- 6.9.2 South America Gastric Motility Disorder Drug Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Gastric Motility Disorder Drug Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Gastric Motility Disorder Drug Sales Value Share by Country, 2024 VS 2031
- 7 Gastric Motility Disorder Drug Country-level Sales and Value Analysis
- 7.1 Global Gastric Motility Disorder Drug Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Gastric Motility Disorder Drug Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Gastric Motility Disorder Drug Sales by Country (2020-2031)
- 7.3.1 Global Gastric Motility Disorder Drug Sales by Country (2020-2025)
- 7.3.2 Global Gastric Motility Disorder Drug Sales by Country (2026-2031)
- 7.4 Global Gastric Motility Disorder Drug Sales Value by Country (2020-2031)
- 7.4.1 Global Gastric Motility Disorder Drug Sales Value by Country (2020-2025)
- 7.4.2 Global Gastric Motility Disorder Drug Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.9.2 France Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.16.2 China Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.19.2 India Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Gastric Motility Disorder Drug Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Gastric Motility Disorder Drug Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Gastric Motility Disorder Drug Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Theravance, Inc.
- 8.1.1 Theravance, Inc. Comapny Information
- 8.1.2 Theravance, Inc. Business Overview
- 8.1.3 Theravance, Inc. Gastric Motility Disorder Drug Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Theravance, Inc. Gastric Motility Disorder Drug Product Portfolio
- 8.1.5 Theravance, Inc. Recent Developments
- 8.2 Targacept, Inc.
- 8.2.1 Targacept, Inc. Comapny Information
- 8.2.2 Targacept, Inc. Business Overview
- 8.2.3 Targacept, Inc. Gastric Motility Disorder Drug Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Targacept, Inc. Gastric Motility Disorder Drug Product Portfolio
- 8.2.5 Targacept, Inc. Recent Developments
- 8.3 Helsinn Healthcare S.A.
- 8.3.1 Helsinn Healthcare S.A. Comapny Information
- 8.3.2 Helsinn Healthcare S.A. Business Overview
- 8.3.3 Helsinn Healthcare S.A. Gastric Motility Disorder Drug Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Helsinn Healthcare S.A. Gastric Motility Disorder Drug Product Portfolio
- 8.3.5 Helsinn Healthcare S.A. Recent Developments
- 8.4 Concert Pharmaceuticals, Inc.
- 8.4.1 Concert Pharmaceuticals, Inc. Comapny Information
- 8.4.2 Concert Pharmaceuticals, Inc. Business Overview
- 8.4.3 Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Product Portfolio
- 8.4.5 Concert Pharmaceuticals, Inc. Recent Developments
- 8.5 ChironWells GmbH
- 8.5.1 ChironWells GmbH Comapny Information
- 8.5.2 ChironWells GmbH Business Overview
- 8.5.3 ChironWells GmbH Gastric Motility Disorder Drug Sales, Value and Gross Margin (2020-2025)
- 8.5.4 ChironWells GmbH Gastric Motility Disorder Drug Product Portfolio
- 8.5.5 ChironWells GmbH Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Gastric Motility Disorder Drug Value Chain Analysis
- 9.1.1 Gastric Motility Disorder Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Gastric Motility Disorder Drug Sales Mode & Process
- 9.2 Gastric Motility Disorder Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gastric Motility Disorder Drug Distributors
- 9.2.3 Gastric Motility Disorder Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


